Management of hepatocellular carcinoma. Where are we now? What's next?;Prise en charge thérapeutique du carcinome hépatocellulaire. Où en sommes-nous? Où allons-nous?

Bulletin du Cancer

Volumn 96, Issue 1, 2009, Pages 19-34

  Taieb, Julien ^a   Barbare, Jean Claude ^b   Boussaha, Tarek ^a   Cunha, Antonio Sa ^c   De Baere, Thierry ^d   Rosmorduc, Olivier ^e   Zucman Rossi, Jessica ^f   Franco, Dominique ^g  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c Groupe Hospitalier Sud CHU de Bordeaux   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f INSERM   (France)

^g HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Chemoembolization; Hepatocellular carcinoma; Liver transplant; Radiofrequency thermal ablation; Sorafenib; Surgical resection

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLEOMYCIN; CARMOFUR; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GANCICLOVIR; GEFITINIB; GEMCITABINE; INTERFERON; IODINATED POPPYSEED OIL; LICARTIN; METUXIMAB I 131; MITOMYCIN C; MITOXANTRONE; NOLATREXED; OXALIPLATIN; PACLITAXEL; PLACEBO; SORAFENIB; SUNITINIB; T 138067; TEGAFUR; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR; VASCULOTROPIN A;

ALOPECIA; ANOREXIA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CHEMOEMBOLIZATION; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; NAUSEA; PALLIATIVE THERAPY; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; ADJUVANT THERAPY; CATHETER ABLATION; DRUG ANTAGONISM; LIVER TUMOR; METHODOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOADJUVANT THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 61549110899     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0790     Document Type: Review

References (102)

1. Trinchet JC, Alperovitch A, Bedossa AP, Degos F, Hainaut P, Van Beers SB. Épidémiologie, prévention, dépistage et diagnostic du carcinome hépatocellular. Bull Cancer 2009 ; 96(1) : 35-43.
2. Hill C, Doyon F. The frequency of cancer in France : mortality trends since 1950 and summary of the report on the causes of cancer. Bull Cancer 2008 ; 95(1) : 5-10.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003 ; 362(9399) : 1907-1 7.
4. Merle P. Epidemiology, natural history and pathogenesis of hepatocellular carcinoma. Cancer Radiother 2005 ; 9(6-7) : 452-7.
5. Rougier P, Mitry E, Barbare JC, Taieb J. Hepatocellular carcinoma (HCC) : an update. Semin Oncol 2007 ; 34(2 Suppl 1) : S12-20.
6. Taieb J, Barbare JC, Rougier P. Medical treatments for hepatocellular carcinoma (HCC) : what's next? Ann Oncol 2006 ; 17(Suppl 10) : x308-x314.
7. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996 ; 334(11) : 693-9.
8. Broelsch CE, Frilling A, Malago M. Should we expand the criteria for liver transplantation for hepatocellular carcinoma-yes, of course! J Hepatol 2005 ; 43(4) : 569-73.
9. Hiatt JR, Carmody IC, Busuttil RW. Should we expand the criteria for hepatocellular carcinoma with living-donor liver transplantation?-No, never, J Hepatol 2005 ; 43(4) : 573-7.
10. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma : expansion of the tumor size limits does not adversely impact survival. Hepatology 2001 ; 33(6) : 1394-403.
11. Hwang S, Lee SG, Joh JW, Suh KS, Kim DG. Liver transplantation for adult patients with hepatocellular carcinoma in Korea : comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 2005 ; 11(10) : 1265-72.
12. Leung JY, Zhu AX, Gordon FD, Pratt DS, Mithoefer A, Garrigan K, et al. Liver transplantation outcomes for early-stage hepatocellular carcinoma : results of a multicenter study. Liver Transpl 2004 ; 10 (11) : 1343-54.
13. Decaens T, Roudot-Thoraval F, Hadni-Bresson S, Meyer C, Gugenheim J, Durand F, et al. Impact of UCSF criteria according to pre-and post-OLT tumor features : analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 2006 ; 12(12) : 1761-9.
14. Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma : experience in Japan. Ann Surg 2004 ; 240(3) : 451-9 (discussion 459-61).
15. Freeman RB, Edwards EB, Harper AM. Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant 2006 ; 6(6) : 1416-21.
16. Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002 ; 50(1) : 123-8.
17. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, Durand F, et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005 ; 11(7) : 767-75.
18. Oldhafer KJ, Chavan A, Frühauf NR, Flemming P, Schlitt HJ, Kubicka S, et al. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma : marked tumor necrosis, but no survival benefit? J Hepatol 1998 ; 29(6) : 953-9.
19. Makuuchi M, Hasegawa H, Yamazaki S. Ultrasonically guided subsegmentectomy. Surg Gynecol Obstet 1985 ; 161(4) : 346-50.
20. Hasegawa K, Kokudo N, Imamura H, Matsuyama Y, Aoki T, Minagawa M, et al. Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg 2005 ; 242(2) : 252-9.
21. Wakai T, Shirai Y, Sakata J, Kaneko K, Cruz PV, Akazawa K, et al. Anatomic resection independently improves long-term survival in patients with T1-T2 hepatocellular carcinoma. Ann Surg Oncol 2007 ; 14(4) : 1356-65.
22. Kaibori M, Matsui Y, Hijikawa T, Uchida Y, Kwon AH, Kamiyama Y. Comparison of limited and anatomic hepatic resection for hepatocellular carcinoma with hepatitis C. Surgery 2006 ; 139(3) : 385-94.
23. Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ, et al. Partial hepatectomy with wide vs narrow resection margin for solitary hepatocellular carcinoma : a prospective randomized trial. Ann Surg 2007 ; 245(1) : 36-43.
24. Dagher I, Lainas P, Carloni A, Caillard C, Champault A, Smadja C, et al. Laparoscopic liver resection for hepatocellular carcinoma. Surg Endosc 2008 ; 22(2) : 372-8.
25. Laurent A, Cherqui D, Lesurtel M, Brunetti F, Tayar C, Fagniez PL. Laparoscopic liver resection for subcapsular hepatocellular carcinoma complicating chronic liver disease. Arch Surg 2003 ; 138 (7) : 763-9 (discussion 769).
26. Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis : a reasonable strategy? Ann Surg 2003 ; 238(4) : 508-18 (discussion 518-9).
27. Bigourdan JM, Jaeck D, Meyer N, Meyer C, Oussoultzoglou E, Bachellier P, et al. Small hepatocellular carcinoma in Child A cirrhotic patients : hepatic resection vs transplantation. Liver Transpl 2003 ; 9(5) : 513-20.
28. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis : Is resection still the treatment of choice? Hepatology 2008 ; 47(1) : 82-9.
29. Poon RT. Optimal initial treatment for early hepatocellular carcinoma in patients with preserved liver function : transplantation or resection? Ann Surg Oncol 2007 ; 14(2) : 541-7.
30. Belghiti J, Cortes A, Abdalla EK, Regimbeau JM, Prakash K, Durand F, et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 2003 ; 238(6) : 885-92 (discussion 892-3).
31. Poon RT, Fan ST. Is primary resection and salvage transplantation for hepatocellular carcinoma a reasonable strategy? Ann Surg 2004 ; 240(5) : 925-8 (author reply 928).
32. Castells A, Bruix J, Bru C, Fuster J, Vilana R, Navasa M, et al. Treatment of small hepatocellular carcinoma in cirrhotic patients : a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993 ; 18(5) : 1121-6.
33. Yamamoto J, Okada S, Shimada K, Okusaka T, Yamasaki S, Ueno H, et al. Treatment strategy for small hepatocellular carcinoma : comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001 ; 34(4 Pt 1) : 707-13.
34. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis : randomized comparison of radio-frequency thermal ablation vs percutaneous ethanol injection. Radiology 2003 ; 228(1) : 235-40.
35. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤ 4 cm. Gastroenterology 2004 ; 127(6) : 1714-23.
36. Guglielmi A, Ruzzenente A, Sandri M, Pachera S, Pedrazzani C, Tasselli S, et al. Radiofrequency ablation for hepatocellular carcinoma in cirrhotic patients : prognostic factors for survival, J Gastrointest Surg 2007 ; 11(2) : 143-9.
37. Vivarelli M, Guglielmi A, Ruzzenente A, Cucchetti A, Bellusci R, Cordiano C, et al. Surgical resection vs percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg 2004 ; 240(1) : 102-7.
38. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006 ; 243(3) : 321-8.
39. Lü MD, Kuang M, Liang LJ, Xie XY, Peng BG, Liu GJ, et al. Surgical resection vs percutaneous thermal ablation for early-stage hepatocellular carcinoma : a randomized clinical trial. Zhonghua Yi Xue Za Zhi 2006 ; 86(12) : 801-5.
40. Yamagiwa K, Shiraki K, Yamakado K, Mizuno S, Hori T, Yagi S, et al. Survival rates according to the Cancer of the Liver Italian Program scores of 345 hepatocellular carcinoma patients after multi-modality treatments during a 10 year period in a retrospective study. J Gastroenterol Hepatol 2008 ; 23(3) : 482-90.
41. Hakimé A, Hines-Peralta A, Peddi H, Atkins MB, Sukhatme VP, Signoretti S, et al. Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy : study in mice. Radiology 2007 ; 244(2) : 464-70.
42. Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis : long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005 ; 234(3) : 961-7.
43. Liu MT, Li SH, Chu TC, Hsieh CY, Wang AY, Chang TH, et al. Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. Jpn J Clin Oncol 2004 ; 34(9) : 532-9.
44. Mornex F, Girard N, Beziat C, Kubas A, Khodri M, Trepo C, et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies-mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 2006 ; 66(4) : 1152-8.
45. Park HC, Seong J, Han KH, Chon CY, Moon YM, Suh CO. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002 ; 54(1) : 150-5.
46. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008 ; 48(Suppl 1) : S 20-37.
47. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma : a randomised trial. Lancet 2000 ; 356(9232) : 802-7.
48. Weng DS, Zhou J, Zhou QM, Zhao M, Wang QJ, Huang LX, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother 2008 ; 31(1) : 63-71.
49. Lau WY, Lai EC, Leung TW, Yu SC. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma : a prospective randomized trial-update on 5 year and 10 year survival. Ann Surg 2008 ; 247(1) : 43-8.
50. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al., Hepatoma Prevention Study Group. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996 ; 334(24) : 1561-7.
51. Hasegawa K, Takayama T, Ijichi M, Matsuyama Y, Imamura H, Sano K, et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma : a randomized trial. Hepatology 2006 ; 44(4) : 891-5.
52. Yamamoto M, Arii S, Sugahara K, Tobe T. Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg 1996 ; 83(3) : 336-40.
53. Ono T, Yamanoi A, Nazmy El Assal O, Kohno H, Nagasue N. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients : metaanalysis of three randomized controlled trials. Cancer 2001 ; 91(12) : 2378-85.
54. Mathurin P, Raynard B, Dharancy S, Kirzin S, Fallik D, Pruvot FR, et al. Meta-analysis : evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther 2003 ; 17(10) : 1247-61.
55. Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007 ; 45(2) : 269-76.
56. Li. HSV Thymidine kinase in Cancer Res. 2007.
57. Söderdahl G, Bäckman L, Isoniemi H, Cahlin C, Höckerstedt K, Broome U, et al. A prospective, randomized, multicentre trial of systemic adjuvant chemotherapy vs no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int 2006 ; 19(4) : 288-94.
58. Hsieh CB, Chou SJ, Shih ML, Chu HC, Chu CH, Yu JC, et al. Preliminary experience with gemcitabine and cisplatin adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 2008 ; 34(8) : 906-10.
59. Llovet JM, Real Ml, Montaña X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation vs symptomatic treatment in patients with unresectable hepatocellular carcinoma : a randomised controlled trial. Lancet 2002 ; 359(9319) : 1734-9.
60. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002 ; 35(5) : 1164-71.
61. Doffoël M, Bonnetain F, Bouché O, Vetter D, Abergel A, Fratté S, et al. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Federation Francophone de Cancerologie Digestive 9402). Eur J Cancer 2008 ; 44(4) : 528-38.
62. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Transarterial therapy for hepatocellular carcinoma : which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007 ; 30(1) : 6-25.
63. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 2006 ; 32(8) : 594-606.
64. Tournoux C, Paoletti X, Barbare JC. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 2007 ; 33(8) : 762-3.
65. Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, et al. A phase l/ll trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007 ; 5(9) : 1100-8.
66. Varela M, Real Ml, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads : efficacy and doxorubicin pharmacokinetics. J Hepatol 2007 ; 46(3) : 474-81.
67. Kulik LM, Carr Bl, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008 ; 47(1) : 71-81.
68. Madden MV, Krige JE, Bailey S, Beningfield SJ, Geddes C, Werner ID, et al. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993 ; 34(11) : 1598-600.
69. Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000 ; 88(9) : 1986-91.
70. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma : how hopeful should we be? Oncologist 2006 : 11(7) : 790-800.
71. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, et al. A randomized phase III study of doxorubicin vs cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005 ; 97(20) : 1532-8.
72. Lau WY, Leung TW, Lai BS, Liew CT, Ho SK, Yu SC, et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg 2001 ; 233(2) : 236-41.
73. Lau WY, Ho SK, Yu SC, Lai EC, Liew CT, Leung TW. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg 2004 ; 240(2) : 299-305.
74. Zerbini A, Pilli M, Ferrari C, Missale G. Is there a role for immunotherapy in hepatocellular carcinoma? Dig Liver Dis 2006 ; 38(4) : 221-5.
75. Taras D, Blanc JF, Rullier A, Dugot-Senant N, Laurendeau I, Vidaud M, et al. Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. J Hepatol 2007 ; 46(1) : 69-76.
76. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001 ; 84(7) : 886-91.
77. Graf H, Jüngst C, Straub G, Dogan S, Hoffmann RT, Jakobs T, et al. Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion 2008 ; 78(1) : 34-8.
78. Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC) : results of a phase II study. Cancer 2007 ; 109(7) : 1384-90.
79. Taieb J, Bonyhay L, Golli L, Ducreux M, Boleslawski E, Tigaud JM, et al. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 2003 ; 98(12) : 2664-70.
80. Asnacios A, Fartoux L, Romano O, Tesmoingt C, Louafi S, Mansoubakht T, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma : results of a multicenter phase II study. Cancer 2008 ; 112(12) : 2733-9.
81. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006 ; 24(12) : 1898-903.
82. Johnson PJ, Billingham LJ. Clinical trial design in hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005 ; 19(1) : 119-27.
83. Tournoux C, De Rycke Y, Médioni J, Asselain B. Methods of joint evaluation of efficacy and toxicity in phase II clinical trials. Contemp Clin Trials 2007 ; 28(4) : 514-24.
84. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005 ; 23(27) : 6657-63.
85. Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, et al. Phase II study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007 ; 110(3) : 581-9.
86. Thomas MB, Dutta A, Brown T, Charnsangavej C, Rashid A, Hoff PM, et al. A phase II open-label study of OSI-774 (NSC 718781) in unresectable hepatocellular carcinoma. Proc Am Soc Clin Oncol 2005.
87. Schwartz JD, Schwartz M, Lehrer D, Coll D, Kinkhabwala M, Sung M, et al. Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. Proc Am Soc Clin Oncol 2006.
88. Sun W, Haller DG, Mykulowycz K, Rosen M, Soulen M, Capparo M, et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC) : a phase II study. Proc Am Soc Clin Oncol 2007.
89. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006 ; 66(24) : 11851-8.
90. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006 ; 24(26) : 4293-300.
91. Faivre SJ, Raymond E, Douillard J, Boucher E, Lim HY, Kim JS, et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients with unresectable hepatocellular carcinoma. Proc Am Soc Clin Oncol 2007.
92. Zhu AX, Sahani DV, di Tomaso E, Duda D, Sindhwani V, Yoon SS, et al. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. Proc Am Soc Clin Oncol.
93. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008 ; 359(4) : 378-90.
94. Fournier LS, Cuénod CA, Clément O, Siauve N, Frija G. Imaging of response to treatment in oncology. J Radiol 2007 ; 88(6) : 829-43.
95. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005 ; 97(13) : 981-9.
96. Regimbeau JM, Kianmanesh R, Farges O, Dondero F, Sauvanet A, Belghiti J. Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma. Surgery 2002 ; 131(3) : 311-7.
97. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005 ; 54(8) : 1151-6.
98. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005 ; 129(1) : 122-30.
99. Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990 ; 11(2) : 181-4.
100. Rougier P, Roche A, Pelletier G, Ducreux M, Pignon JP, Etienne JP. Efficacy of chemoembolization for hepatocellular carcinomas : experience from the Gustave Roussy Institute and the Bicetre Hospital. J Surg Oncol Suppl 1993 ; 3 : 94-6.
101. Groupe d'étude et de traitement du carcinome hépatocellu- laire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995 ; 332(19) : 1256-61.
102. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagège H, Dao T, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization : a multicenter randomized trial. Groupe CHC. J Hepatol 1998 ; 29(1) : 129-34.